Organovo (NASDAQ:ONVO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research note published on Wednesday. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Trading Down 14.5 %

Organovo stock opened at $3.14 on Wednesday. The stock has a market cap of $53.89 million, a P/E ratio of -3.69 and a beta of 0.45. The stock has a 50 day moving average of $5.09 and a 200-day moving average of $5.24. Organovo has a 52 week low of $3.04 and a 52 week high of $21.96.

Organovo (NASDAQ:ONVO) last released its earnings results on Wednesday, February 19th. The medical research company reported ($2.28) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.24. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. As a group, equities analysts predict that Organovo will post -0.77 earnings per share for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.